Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZACTIMA plus mFOLFOX6 versus mFOLFOX6 alone in previously treated metastatic colorectal cancer
2006-005022-23Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Started Jan 2007; status: completed.
02
Drugs
vandetanib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-005022-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005022-23.